ADMA BIOLOGICS INC (ADMA) Stock News
NASDAQ:ADMA - Nasdaq - US0008991046 - Common Stock - Currency: USD
ADMA Latest News, Press Relases and Analysis
ADMA BIOLOGICS INC (NASDAQ:ADMA) is not too expensive for the growth it is showing.
Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Are Options Traders Betting on a Big Move in ADMA Biologics Stock?
Investors need to pay close attention to ADMA Biologics stock based on the movements in the options market lately.
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
Puma Biotechnology beats on first-quarter 2025 earnings and sales. Stock rises in after-hours trading
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?
ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025. We recommend the stock to prospective investors.
Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains
VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.
Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits
The company makes immunoglobulin products using donated plasma.
Mentions: HIMS
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of -12.50% and 3.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BHST
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51%...
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down
KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall
Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025. Stock down.
3 Mid-Cap Medical Stocks Outperforming the Market
Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness.
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened
Vertex reports weaker-than-expected first-quarter 2025 results. The company tightens its total revenue guidance for 2025.
Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised
ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance.
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?
Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals.
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected. Stock declines.
Has ADMA Biologics (ADMA) Outpaced Other Medical Stocks This Year?
Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year.
Mentions: AGL
Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know
Zacks.com users have recently been watching Adma Biologics (ADMA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y
SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ET
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ET...
Why GRAIL, Inc. (GRAL) is Surging in 2025
We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where GRAIL, Inc. (NASDAQ:GRAL) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader market in 2024, many healthcare stocks are making a comeback […]
Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Adma Biologics (ADMA) closed the most recent trading day at $24.11, moving -1.63% from the previous trading session.